Patents by Inventor Peter Eamon Molloy

Peter Eamon Molloy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIGH AFFINITY NY-ESO T CELL RECEPTORS
    Publication number: 20110014169
    Abstract: The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a KD for the said that peptide-HLA complex of less than or equal to 1 ?M and/or have an off-rate (koff) of 1×10?3 S?1 or slower.
    Type: Application
    Filed: August 11, 2010
    Publication date: January 20, 2011
    Applicant: IMMUNOCORE LIMITED
    Inventors: Jonathan Michael Boulter, Bent Karsten Jakobsen, Yi Li, Peter Eamon Molloy, Steven Mark Dunn, Lucy Boulter
  • T CELL RECEPTOR DISPLAY
    Publication number: 20100113300
    Abstract: A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed.
    Type: Application
    Filed: October 21, 2009
    Publication date: May 6, 2010
    Applicant: IMMUNOCORE LIMITED
    Inventors: Bent Karsten Jakobsen, Torben Bent Andersen, Peter Eamon Molloy, Yi Li, Jonathan Michael Boulter
  • High Affinity Hiv T Cell Receptors
    Publication number: 20090214551
    Abstract: The present invention provides TCRs having an affinity (KD) of less than or equal to 1 ?M, and/or an off-rate (koff) of 1×10?3S?1 or slower, for the SLYNTVATL-HLA-A*0201 complex provided that when the said TCR is presented by cell and comprises SEQ ID NOS:1 and 2, the cell is not a native T cell. Such TCRs are useful, either alone or associated with a therapeutic agent, for targeting HIV infected cells presenting that complex.
    Type: Application
    Filed: March 29, 2006
    Publication date: August 27, 2009
    Applicant: AVIDEX LTD.
    Inventors: Bent Karsten Jakobsen, Yi Li, Steven Mark Dunn, Peter Eamon Molloy